A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 08 2021
25 08 2021
Historique:
received:
13
05
2021
accepted:
06
08
2021
entrez:
26
8
2021
pubmed:
27
8
2021
medline:
4
9
2021
Statut:
epublish
Résumé
Chronic hepatitis B virus (HBV) infection is a major public health threat for migrant populations in Spain and efforts to scale up testing are needed to reach the WHO elimination targets. The Hepatitis B Virus Community Screening and Vaccination in Africans (HBV-COMSAVA) study aims to use point-of-care testing and simplified diagnostic tools to identify, link to care, or vaccinate African migrants in Barcelona during the COVID-19 pandemic. From 21/11/20 to 03/07/2021, 314 study participants were offered HBV screening in a community clinic. Rapid tests for HBsAg screening were used and blood samples were collected with plasma separation cards. Patients received results and were offered: linkage to specialist care; post-test counselling; or HBV vaccination in situ. Sociodemographic and clinical history were collected and descriptive statistics were utilized. 274 patients were included and 210 (76.6%) returned to receive results. The HBsAg prevalence was 9.9% and 33.2% of people had evidence of past resolved infection. Overall, 133 required vaccination, followed by post-test counselling (n = 114), and linkage to a specialist (n = 27). Despite the COVID-19 pandemic, by employing a community-based model of care utilizing novel simplified diagnostic tools, HBV-COMSAVA demonstrated that it was possible to diagnose, link to care, and vaccinate African migrants in community-based settings.
Identifiants
pubmed: 34433852
doi: 10.1038/s41598-021-96350-3
pii: 10.1038/s41598-021-96350-3
pmc: PMC8387363
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17063Informations de copyright
© 2021. The Author(s).
Références
Public Health Rev. 2016 Dec 3;37:28
pubmed: 29450069
Viruses. 2010 Aug;2(8):1504-9
pubmed: 21994691
Int J Infect Dis. 2010 Dec;14(12):e1024-31
pubmed: 20870439
BMJ Glob Health. 2021 Jan;6(1):
pubmed: 33402334
Int J Environ Res Public Health. 2018 Sep 01;15(9):
pubmed: 30200406
J Hepatol. 2015 Feb;62(2):469-76
pubmed: 25457207
Pan Afr Med J. 2019 Jun 10;33:96
pubmed: 31489074
Clin Infect Dis. 2016 Jun 1;62 Suppl 4:S289-97
pubmed: 27190318
J Hepatol. 2013 May;58(5):890-7
pubmed: 23333446
PLoS One. 2020 Jun 12;15(6):e0234348
pubmed: 32530945
BMC Med. 2017 May 3;15(1):92
pubmed: 28464883
Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):451-452
pubmed: 31320742
Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101564
pubmed: 33740477
J Gastroenterol Hepatol. 2020 Sep;35(9):1570-1578
pubmed: 31957902
Rev Esp Salud Publica. 2014 Nov-Dec;88(6):811-8
pubmed: 25418570
Epidemiol Infect. 2017 Oct;145(14):2873-2885
pubmed: 28891457
Am J Trop Med Hyg. 2018 Jan;98(1):319-325
pubmed: 29165212
J Viral Hepat. 2019 Dec;26(12):1431-1453
pubmed: 31332919
BMC Med. 2016 Oct 21;14(1):166
pubmed: 27769239
J Virol Methods. 2021 Mar;289:114039
pubmed: 33338545
Bull World Health Organ. 2021 Apr 1;99(4):280-286
pubmed: 33953445
Vaccine. 2012 Mar 9;30(12):2212-9
pubmed: 22273662
Rev Esp Salud Publica. 2014 Nov-Dec;88(6):715-34
pubmed: 25418563
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243354
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):135-184
pubmed: 30647010
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):792-794
pubmed: 32730783